<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04240327</url>
  </required_header>
  <id_info>
    <org_study_id>20190864</org_study_id>
    <secondary_id>U01CA239141-01A1</secondary_id>
    <secondary_id>NCI-2020-05157</secondary_id>
    <nct_id>NCT04240327</nct_id>
  </id_info>
  <brief_title>Marker Driven Selection of Patients for Prostate Biopsy and Management</brief_title>
  <acronym>MDSelect</acronym>
  <official_title>Marker Driven Selection of Patients for Prostate Biopsy and Management: The University of Miami MDSelect Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to determine if the interpretation of multiparametric&#xD;
      MRI (mpMRI) with an algorithm called habitat risk score (HRS) in combination with a panel of&#xD;
      blood and urine biomarkers is more effective at detecting prostate cancer than standard of&#xD;
      care interpretation of mpMRI with the Prostate Imaging Reporting and Data System (PIRADS).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 29, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Negative Predictive Value (NPV) for ruling out GG2+ prostate cancer via Habitat Risk Score (HRS) MRI Interpretation software combined with a panel of blood and urine biomarkers, versus via standard of care (SoC) MRI interpretation with PIRADS v2.</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>The investigators will assess whether automated quantitative HRS MRI interpretation software combined with a panel of blood and urine biomarkers incrementally improves the negative predictive value for ruling out GG2+ cancer on prostate biopsy by 30% or more above standard of care (SoC) MRI interpretation with PIRADS v2.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NPV for ruling out GG2+ prostate cancer via HRS MRI Interpretation software versus via SoC MRI interpretation with PIRADS v2</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>The investigators will assess whether automated quantitative HRS MRI interpretation software can incrementally improve the negative predictive value (NPV) for ruling out GG2+ cancer on prostate biopsy by 20% or more above SoC MRI interpretation with PIRADS v2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NPV for ruling out GG2+ prostate cancer by a panel of blood and urine biomarkers versus via SoC MRI interpretation with PIRADS v2</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>The investigators will assess whether a panel of blood and urine biomarkers can incrementally improve the negative predictive value (NPV) for ruling out GG2+ cancer on prostate biopsy by 10% or more above SoC MRI interpretation with PIRADS v2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NPV for ruling out clinically significant prostate cancer via HRS MRI interpretation software combined with a panel of blood and urine biomarkers versus via SoC MRI interpretation with PIRADS v2</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>The investigators will assess whether automated quantitative HRS MRI interpretation software combined with a panel of blood and urine biomarkers incrementally improves the negative predictive value for ruling out clinically significant prostate cancer (defined as any GG2+ cancer OR 50% or more cores of GG1 cancer) on prostate biopsy by 30% or more above standard of care MRI interpretation with PIRADS v2</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>PSA</condition>
  <condition>Elevated PSA</condition>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>GG2+ Prostate Cancer Risk</arm_group_label>
    <description>Participants at risk for Grade Group 2 (GG2+) prostate cancer. Participants will be followed for up to two years to rule out the presence of GG2+ prostate cancer</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Biopsy Tissue, blood and urine&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Study participants will be targeted for enrollment from a consecutive cohort of men who are&#xD;
        referred to the University of Miami for prostate cancer evaluation and management, which&#xD;
        includes internal and external physician referrals, most often due to an increased PSA,&#xD;
        and/or abnormal digital rectal exam (DRE).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male participant, aged 40-85 years.&#xD;
&#xD;
          2. In good general health as evidenced by medical history.&#xD;
&#xD;
          3. Referred for a biopsy of the prostate for evaluation of prostate cancer due to&#xD;
             elevated or increasing prostate-specific antigen (PSA) or an abnormal digital rectal&#xD;
             exam (DRE).&#xD;
&#xD;
          4. Participant must agree to forego testosterone supplementation during the duration of&#xD;
             the study due to unknown impacts on prostate cancer biomarkers.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous or current history of prostate cancer or treatment for prostate cancer.&#xD;
&#xD;
          2. Previous history of pelvic radiation.&#xD;
&#xD;
          3. Known allergic reactions to MRI contrast or inability to undergo MRI due to renal&#xD;
             toxicity.&#xD;
&#xD;
          4. Inability to undergo blood draw or biopsy of the prostate as per protocol.&#xD;
&#xD;
          5. Prior MRI guided biopsy of the prostate for prostate cancer evaluation.&#xD;
&#xD;
          6. Previous prostate biopsy or prostate procedure within 6 months of enrollment within&#xD;
             the trial.&#xD;
&#xD;
          7. Standard contraindications to MRI, such as allergies to contrast die, renal toxicity,&#xD;
             ferromagnetic metal in body/eye, pacemaker, defibrillator, other mechanical device, or&#xD;
             extreme claustrophobia (medication with anti-anxiety agents, such as Ativan, may be&#xD;
             attempted) will prevent eligibility and will be applied for all protocol-related MRIs.&#xD;
&#xD;
          8. Patients with impaired decision-making capacity.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sanoj Punnen, MD, MAS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elena M Cortizas, MS</last_name>
    <phone>305-243-6438</phone>
    <email>ecortizas@med.miami.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena M Cortizas, MS</last_name>
      <phone>305-243-6438</phone>
      <email>ecortizas@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Sanoj Punnen, MD, MAS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 20, 2020</study_first_submitted>
  <study_first_submitted_qc>January 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2020</study_first_posted>
  <last_update_submitted>October 8, 2021</last_update_submitted>
  <last_update_submitted_qc>October 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Sanoj Punnen, MD, MAS</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

